Published in J Am Coll Surg on August 01, 2003
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer (MILO) | NCT02243059
Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer (2006) 1.67
Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. PLoS Genet (2016) 1.39
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer (2005) 1.08
Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncol (2013) 1.06
Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res (2012) 1.04
Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol (2010) 0.94
Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer (2011) 0.92
Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget (2016) 0.87
Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. Int J Gynecol Cancer (2015) 0.86
Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health (2014) 0.81
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. Reprod Biol Endocrinol (2014) 0.80
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute. Int J Surg Oncol (2010) 0.78
Role of primary surgery in advanced ovarian cancer. World J Surg Oncol (2004) 0.78
Sentinel node in ovarian cancer: study protocol for a phase 1 study. Trials (2013) 0.77
Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature. World J Surg Oncol (2010) 0.77
Cytoreductive surgery in ovarian cancer. Cancer Imaging (2007) 0.75
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer (2016) 0.75
Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population? Dis Markers (2014) 0.75
Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep (2017) 0.75
Management of retroperitoneal lymph nodes in the treatment of ovarian cancer. Int J Clin Oncol (2007) 0.75
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol (2011) 2.35
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol (2005) 2.07
The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. Am J Obstet Gynecol (2012) 2.01
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]. Bull Cancer (2004) 1.80
Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol (2009) 1.77
Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol (2004) 1.75
Randomized trial of laparoscopically assisted versus open colorectal resection for endometriosis: morbidity, symptoms, quality of life, and fertility. Ann Surg (2010) 1.74
Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril (2008) 1.72
External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol (2008) 1.71
Quality of life after laparoscopic colorectal resection for endometriosis. Hum Reprod (2006) 1.66
Use of the sentinel node procedure to stage endometrial cancer. Ann Surg Oncol (2008) 1.54
Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol (2010) 1.53
Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol (2007) 1.52
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery (2005) 1.51
Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol (2007) 1.50
Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol (2005) 1.49
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol (2007) 1.48
Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol (2009) 1.48
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol (2007) 1.44
Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol (2010) 1.43
A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol (2005) 1.41
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
The "definitive" trial of surgical cytoreduction in advanced-stage ovarian cancer. Int J Gynecol Cancer (2013) 1.39
First case of a centropelvic recurrence after radical trachelectomy: literature review and implications for the preoperative selection of patients. Gynecol Oncol (2004) 1.37
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer (2010) 1.31
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol (2009) 1.25
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer (2004) 1.22
Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature. Fertil Steril (2007) 1.22
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol (2011) 1.20
Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology (2010) 1.19
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol (2009) 1.18
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14
Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg (2003) 1.13
Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? J Clin Endocrinol Metab (2006) 1.13
Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and müllerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab (2008) 1.12
Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging (2008) 1.12
Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res (2005) 1.11
Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol (2012) 1.10
Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers. Hum Reprod (2009) 1.10
Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol (2010) 1.10
Outcome of laparoscopic colorectal resection for endometriosis. Curr Opin Obstet Gynecol (2007) 1.10
Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol (2010) 1.09
Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 1.09
Aberrant expression of ovary determining gene FOXL2 in the testis and juvenile granulosa cell tumor in children. J Urol (2008) 1.08
Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity. Ann Surg Oncol (2007) 1.08
Longterm followup of posthysterectomy vaginal vault prolapse abdominal repair: a report of 85 cases. J Am Coll Surg (2002) 1.07
MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol (2003) 1.07
Breast cancer stroma frequently recruits fetal derived cells during pregnancy. Breast Cancer Res (2008) 1.07
Conservative management of low-grade endometrial stromal sarcoma followed by pregnancy and severe recurrence. Anticancer Res (2009) 1.05
Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer. Oncologist (2010) 1.05
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery (2003) 1.05
Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis (2006) 1.04
Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol (2006) 1.02